| dbo:abstract | - 3C-DFE is a lesser-known psychedelic drug, which is a fluorinated derivative of 3C-E. It was first synthesised by Daniel Trachsel in 2002, and has been reported as showing similar psychedelic activity to related compounds, with a dose range of around 20–40 mg and a duration of approximately 10 hours. Despite its reported psychedelic activity, binding studies in vitro showed 3C-DFE to have a surprisingly weak binding affinity of 2695 nM at 5-HT2A with negligible affinity at 5-HT2C, making it only slightly higher affinity than mescaline, despite its higher potency in vivo. (en)
|
| dbo:alternativeName | |
| dbo:iupacName | - 1-[4-(2,2-Difluoroethoxy)-3,5-dimethoxyphenyl]propan-2-amine (en)
|
| dbo:thumbnail | |
| dbo:wikiPageID | |
| dbo:wikiPageLength | - 2869 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID | |
| dbo:wikiPageWikiLink | |
| dbp:imagefile | |
| dbp:othernames | |
| dbp:pin | |
| dbp:wikiPageUsesTemplate | |
| dcterms:subject | |
| rdf:type | |
| rdfs:comment | - 3C-DFE is a lesser-known psychedelic drug, which is a fluorinated derivative of 3C-E. It was first synthesised by Daniel Trachsel in 2002, and has been reported as showing similar psychedelic activity to related compounds, with a dose range of around 20–40 mg and a duration of approximately 10 hours. Despite its reported psychedelic activity, binding studies in vitro showed 3C-DFE to have a surprisingly weak binding affinity of 2695 nM at 5-HT2A with negligible affinity at 5-HT2C, making it only slightly higher affinity than mescaline, despite its higher potency in vivo. (en)
|
| rdfs:label | |
| owl:sameAs | |
| prov:wasDerivedFrom | |
| foaf:depiction | |
| foaf:isPrimaryTopicOf | |
| isdbo:wikiPageRedirects of | |
| isdbo:wikiPageWikiLink of | |
| isfoaf:primaryTopic of | |
